Immunocore gives Q3 sales


United Kingdom

Immunocore Holdings Plc, a developer of T cell receptor immunotherapies, has reported third quarter revenue for its first approved product, Kimmtrak (tebentafusp), for metastatic uveal melanoma. The therapy was approved in both the US and the EU in 2022. In the third quarter Kimmtrak delivered net sales of £49.7 million, an increase of 9% from a year earlier. Of this sum, £34.5 million was generated in the US; £15 million from Europe; and £0.2 million from the rest of the world. Since its first authorisation, Kimmtrak has been approved in more than 35 countries.